Depo Medrol80 mg/2 ml

Indications of Depo Medrol

Depo Medrol is a long-acting (depot) corticosteroid suspension used by injection. Its indications are classified below by the route of injection and strength of clinical evidence.

Established/Approved Uses

• Intra-articular or soft-tissue injection: Adjunctive short-term therapy for acute flares of osteoarthritis, rheumatoid arthritis, acute gouty arthritis, bursitis, tenosynovitis, and epicondylitis, when localized anti-inflammatory effect is desired.
• Intralesional injection: Keloids, localized hypertrophic and inflammatory lesions of lichen planus, psoriatic plaques, alopecia areata, and discoid lupus erythematosus.
• Intramuscular (systemic) injection: Used as a long-acting alternative to oral corticosteroids for systemic anti-inflammatory or immunosuppressive effect in conditions such as severe allergic reactions/allergic states, dermatologic diseases, endocrine disorders, selected gastrointestinal diseases, hematologic disorders, ophthalmic inflammatory diseases, respiratory diseases (including symptomatic sarcoidosis), and rheumatic disorders, when a depot (long-acting) corticosteroid effect is appropriate.

Adjunct/Combination Use

In many of the above systemic conditions, Depo Medrol is used as an adjunct to, or as a substitute depot form of, standard disease-directed therapy (e.g., disease-modifying agents in rheumatoid arthritis) rather than as sole therapy for the underlying disease.

Note: Depo Medrol is intended for intramuscular, intra-articular, soft-tissue, and intralesional use only. It must never be given intravenously or intrathecally/epidurally (see Contraindications).

Each mL of Methyl Prednisolone Acetate injectable suspension typically contains methylprednisolone acetate equivalent to 40 mg or 80 mg of methylprednisolone, as a sterile, aqueous suspension for injection, along with suspending and preservative agents. Available strengths may vary by manufacturer; check the product label for the exact strength dispensed.

Depo Medrol is a synthetic glucocorticoid formulated as a sterile suspension for injection. Because the acetate ester is poorly water-soluble, it forms a "depot" at the injection site, releasing methylprednisolone slowly over days to weeks. This makes Depo Medrol suitable for localized intra-articular/soft-tissue therapy and for long-acting systemic anti-inflammatory or immunosuppressive treatment given by intramuscular injection.

Depo Medrol is not water-clear like a solution — it is a suspension and must be shaken well before use. It is not intended for intravenous or intrathecal/epidural administration.

Corticosteroid (glucocorticoid) — depot/long-acting injectable suspension. Depo Medrol belongs to this class.

Pharmacology of Methyl Prednisolone Acetate

Methyl Prednisolone Acetate is a glucocorticoid that binds intracellular glucocorticoid receptors, which then modulate gene transcription to produce anti-inflammatory and immunosuppressive effects. It inhibits phospholipase A2, reducing the release of arachidonic acid and downstream prostaglandins and leukotrienes; suppresses migration of neutrophils and monocytes to sites of inflammation; reduces capillary permeability; and stabilizes lysosomal membranes.

Because Methyl Prednisolone Acetate is an acetate ester suspension, it is absorbed slowly from the injection site, producing a prolonged (depot) duration of action compared with soluble corticosteroid preparations such as methylprednisolone sodium succinate.

Depo Medrol suspension should be shaken well immediately before use to ensure uniform dosing. It is administered by a healthcare professional using aseptic technique:

• Intramuscular injection for systemic effect.
• Intra-articular injection directly into the affected joint, only after infection in that joint has been excluded.
• Soft-tissue or intralesional injection for localized lesions.

Depo Medrol must never be given intravenously, and must never be given by the intrathecal or epidural route. Each vial/ampoule is intended for single-patient/single-session use where possible; discard any unused suspension per facility protocol to reduce contamination risk.

Drug Interactions with Depo Medrol

• NSAIDs: Concurrent use with Depo Medrol increases the risk of gastrointestinal ulceration and bleeding.
• Other immunosuppressants: Combining Depo Medrol with other immunosuppressive drugs increases the risk of infection due to additive immune suppression.
• Live or live-attenuated vaccines: Should be avoided during treatment with immunosuppressive doses of Depo Medrol, as antibody response may be reduced and vaccine-strain infection may occur.
• Antidiabetic medications (insulin, oral agents): Depo Medrol can raise blood glucose; dose adjustment of antidiabetic therapy may be needed.
• Warfarin and other anticoagulants: Depo Medrol may alter anticoagulant response (increased or decreased effect); INR should be monitored more closely.
• Potassium-depleting agents (e.g., diuretics, amphotericin B): Concurrent use with Depo Medrol increases the risk of hypokalemia.
• CYP3A4 inhibitors (e.g., ketoconazole) and inducers (e.g., rifampin, phenytoin): May increase or decrease methylprednisolone levels/effect respectively when combined with Depo Medrol.

Side Effects of Depo Medrol

Local (Injection-Related) Effects

• Injection-site atrophy, depigmentation, or subcutaneous fat atrophy, especially with repeated injection at the same site.
• Post-injection flare (transient increase in pain/inflammation).
• Joint infection — rare, but serious, if aseptic technique is not maintained during intra-articular injection.

Systemic Effects

• Hyperglycemia or worsening of diabetes control.
• Hypertension and fluid retention.
• Osteoporosis and increased fracture risk with repeated/prolonged systemic dosing.
• Adrenal suppression, particularly with repeated systemic dosing.
• Increased susceptibility to infections, and masking of signs of infection.
• Mood changes, insomnia, or psychiatric disturbances.
• Cushingoid features (weight gain, facial rounding) with repeated or prolonged use.
• Cataracts and increased intraocular pressure/glaucoma with prolonged use.

Pregnancy and Lactation with Depo Medrol

Pregnancy: Corticosteroids, including Depo Medrol, have shown teratogenic effects in animal studies, and adequate, well-controlled studies in pregnant women are lacking. Depo Medrol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Infants born to mothers who received substantial doses of Depo Medrol during pregnancy should be monitored for signs of hypoadrenalism. Use should always be discussed with, and supervised by, a physician.

Lactation: Corticosteroids given systemically, including Depo Medrol, are excreted in human breast milk. Because of the potential for adverse effects in the nursing infant, a decision should be made whether to discontinue breastfeeding or discontinue Depo Medrol, taking into account the importance of treatment to the mother — only under medical advice.

Precautions and Warnings for Depo Medrol

• Depo Medrol is a depot (long-acting) corticosteroid suspension intended only for intramuscular, intra-articular, soft-tissue, or intralesional injection. It must never be given intravenously, and never by the intrathecal or epidural route (see Contraindications).
• Repeated intra-articular injections of Depo Medrol into the same joint should be limited in frequency and total number, as excessive use can accelerate cartilage/joint damage.
• Repeated systemic dosing with Depo Medrol carries a risk of hypothalamic-pituitary-adrenal (HPA) axis suppression; dose should be tapered gradually after prolonged use rather than stopped abruptly.
• Depo Medrol can mask signs of infection and increase susceptibility to new infections; live vaccines should be avoided during immunosuppressive therapy.
• Use with caution in patients with peptic ulcer disease, diabetes mellitus, hypertension, congestive heart failure, osteoporosis, glaucoma/cataracts, or psychiatric disturbance, as Depo Medrol may worsen these conditions.
• Aseptic technique is essential during administration to reduce the risk of joint or soft-tissue infection.
• Anaphylactoid/hypersensitivity reactions have been reported rarely with Depo Medrol; administer under conditions where such reactions can be managed.

Overdose with Depo Medrol

Acute overdosage with Depo Medrol is unlikely to be life-threatening. Reported and expected symptoms of overdosage are generally an extension of the known pharmacologic and adverse effects (e.g., marked fluid retention, elevated blood pressure, elevated blood glucose). There is no specific antidote. If overdose is suspected, seek immediate medical attention or contact emergency services/poison control; management is supportive and symptomatic, with treatment individualized by a physician based on the clinical situation. Do not attempt to manage a suspected overdose at home without medical guidance.

Store Depo Medrol at controlled room temperature, generally 20–25°C (68–77°F) and below 30°C, protected from light and from freezing. Shake well before use. Keep out of reach of children. Discard any unused suspension remaining after the intended dose has been withdrawn, as Depo Medrol vials are generally intended for single-use.

Use of Depo Medrol in Special Populations

• Elderly: Depo Medrol should be used with caution, as older adults may be at greater risk of osteoporosis, hypertension, hypokalemia, diabetes, and skin fragility from corticosteroid therapy.
• Hepatic impairment: Patients with hepatic impairment may have altered metabolism of Depo Medrol and may require closer monitoring; use with caution.
• Renal impairment: Use Depo Medrol with caution; fluid and electrolyte effects (sodium/fluid retention, potassium loss) may be more pronounced.
• Diabetes mellitus: Depo Medrol can worsen glycemic control; blood glucose monitoring and antidiabetic dose adjustment may be required.
• Immunocompromised patients: Additional caution is needed, as Depo Medrol further suppresses immune response and can reactivate latent infections (e.g., tuberculosis, strongyloidiasis).

The duration of treatment with Depo Medrol is determined by the treating physician based on the condition, response, and route of administration. Intra-articular or soft-tissue injections are generally intended for short-term, intermittent use for flares, with repeat injections into the same joint spaced apart (commonly not more often than every few weeks to months) and limited in total number per year to reduce the risk of joint damage. Systemic (intramuscular) use for a chronic condition should be for the shortest duration and lowest dose/frequency that controls symptoms, with periodic reassessment, due to the cumulative risks of adrenal suppression, osteoporosis, and other long-term corticosteroid effects.

Corticosteroids; Glucocorticoids; Depot (long-acting) injectable corticosteroid suspensions. Methyl Prednisolone Acetate is a member of this class.

Mode of Action of Methyl Prednisolone Acetate

Methyl Prednisolone Acetate acts as a glucocorticoid receptor agonist. After entering cells, it binds cytoplasmic glucocorticoid receptors; the receptor-drug complex translocates to the nucleus and alters transcription of genes involved in inflammation, resulting in decreased synthesis of pro-inflammatory mediators (e.g., prostaglandins, leukotrienes, cytokines) and increased synthesis of anti-inflammatory proteins (e.g., lipocortin, which inhibits phospholipase A2). Clinically, this produces anti-inflammatory, immunosuppressive, and anti-allergic effects. The acetate ester in Methyl Prednisolone Acetate confers low water solubility, so after intramuscular or intra-articular injection it forms a depot that is slowly hydrolyzed and absorbed, extending its duration of action to days or weeks.

C

Pediatric Use of Depo Medrol

The efficacy and safety profile of Depo Medrol in children is generally similar to that in adults for the same indications, but pediatric patients are more susceptible to certain corticosteroid effects. Depo Medrol can cause decreased growth velocity in infants, children, and adolescents even at relatively low systemic doses, and this effect may be irreversible; growth and development should be monitored closely during prolonged or repeated use. Children on Depo Medrol therapy should also be monitored for blood pressure, weight, height, intraocular pressure, and signs of infection, and the lowest effective dose/frequency should be used. Safety and efficacy of Depo Medrol for intra-articular or intralesional use in young children have not been well established, and use in this population should be at the discretion of a pediatric specialist.